ER920W Showcased at HRS Conference
MINNEAPOLIS, June 12 /PRNewswire-FirstCall/ -- Braemar, Inc., a subsidiary of Biotel, Inc. (OTC Bulletin Board: BTEL) and a world leader in ambulatory cardiac monitoring devices, has introduced the ER920W, an advanced wireless device that integrates cardiac arrhythmia monitoring and cell phone technologies in one unit. The ER920W is a digital loop recorder with on-board arrhythmia detection algorithms for automatic detection, recording and immediate transmission of patient data files to a service center for analysis and physician attention. Transmission occurs without patient interaction and without connection through a separate cell phone, reducing potential anomalies in the prescribed testing routine and avoiding the possibility of the patient forgetting to carry the cell phone. The device, which has FDA 510(k) clearance, was showcased at the recent Heart Rhythm Society (HRS) conference in San Francisco.
The ER920W connects the patient to a 24/7 monitoring center. Its telecommunications architecture, including cellular network, Internet and Braemar's proprietary LINX Management software interface, allows for bidirectional data flow, so the physician can monitor the patient's cardiac events and remotely program the device as required. The cellular transmitter embedded in the ER920W uses a "Quad-Band" modem for maximum flexibility and is compatible with both GSM and GPRS cellular networks.
"The ER920W is an advanced arrhythmia monitor with proprietary technology that we believe represents the next generation of cardiac event monitoring," Harry Strandquist, President of Braemar, Inc. said. "The ER920W provides faster patient diagnosis, improves patient compliance and is far superior to the current cumbersome transmission method. This device is the first in a series of Braemar wireless arrhythmia monitoring products currently under development."
Cardiac arrhythmia monitors are worn by patients for up to 30 days to
document and record transient cardiac events. Recording of symptomatic
events such as syncope, palpitations, dizziness, chest discomfort and
shortness of breath is activated by the patient. The ER920W enhances
diagnostic yield with embedded algorithms that automatically detect, record
and immediately transmit asymptomatic events such as atrial fibrillation,
bradycardia, tachycardia and cardiac pause.
A photo of the ER920W is available at http://www.biotelinc.com/images/BraemarER920W.jpg.
Braemar, Inc., designs, develops, engineers and manufactures ambulatory cardiac monitoring and other medical devices. The company provides high-quality, reliable devices to OEM partners worldwide.
|SOURCE Braemar, Inc.|
Copyright©2008 PR Newswire.
All rights reserved